BBL
VRTX icon

Beck Bode LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

Beck Bode LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-28,875
Closed -$11.7M – 141
2023
Q4 		$11.7M Buy
28,875
+21,934
+316% +$8.1M 2.64% 4
2023
Q3 		$2.41M Sell
6,941
-112
-2% -$39.2K 0.62% 52
2023
Q2 		$2.48M Sell
7,053
-403
-5% -$136K 0.6% 55
2023
Q1 		$2.35M Sell
7,456
-1,191
-14% -$357K 0.58% 58
2022
Q4 		$2.5M Buy
8,647
+1,371
+19% +$418K 0.56% 59
2022
Q3 		$2.11M Buy
7,276
+2,342
+47% +$674K 0.46% 65
2022
Q2 		$1.39M Buy
4,934
+4,065
+468% +$1.09M 0.3% 75
2022
Q1 		$227K Buy
+869
New +$206K 0.05% 143
2021
Q4 		– Sell
-53,823
Closed -$9.76M – 104
2021
Q3 		$9.76M Buy
53,823
+53,813
+538,130% +$10.5M 2.72% 15
2021
Q2 		$2K Buy
+10
New +$2.09K ﹤0.01% 303
2020
Q4 		– Sell
-387
Closed -$105K – 270
2020
Q3 		$105K Buy
+387
New +$107K 0.04% 78

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Beck Bode LLC's VRTX Position: Q1 2024 in Review

Beck Bode LLC sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 28,875 shares — an estimated $11.7M sold.

Beck Bode LLC first reported a position in VRTX in Q3 2020 and held it in 11 quarters. The position peaked at $11.7M in Q4 2023. 1,496 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • Beck Bode LLC reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Beck Bode LLC sold 28,875 Vertex Pharmaceuticals shares in Q1 2024, an estimated $11.7M.
  • Beck Bode LLC first reported a position in Vertex Pharmaceuticals in Q3 2020 and held it in 11 quarters.
  • Beck Bode LLC's Vertex Pharmaceuticals position peaked at $11.7M in Q4 2023.
  • 1,496 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Beck Bode LLC's 13F filing for Q1 2024, filed 22 May 2024.